Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings, Inc. (“Amarantus”) is a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis (programmed cell death).
The Company’s lead therapeutic program Mesencephalic-Astrocyte-derived Neurotrophic Factor, or MANF is a targeted therapeutic to address the underlying Programmed Cell Death (Apoptosis) associated with a wide range of devastating human disorders with a priority to identify drug able orphan indications including Retinitis Pigmentosa.
The LymPro Test® is the Company's flagship blood test for Alzheimer's disease. LymPro was designed with the purpose of diagnosing Alzheimer’s in its mild to moderate stage. This patient-specific identification has the potential to become an invaluable tool for Alzheimer’s disease clinical trials, where there has been a well-documented history of patient recruitment errors related to inaccurate diagnosis of Alzheimer’s
Management Team and Board of Advisors have designed a business strategy to formulate and advance pre-clinical and clinical programs for the Company's product candidates through successive de-risking milestones in order to maximize their commercial potential. The Company is also focused on making the assets attractive partnering targets for product development focused biotechnology, pharmaceutical, medical device and diagnostic companies.
- Sep 12 2014, 10:30 AM EDT